Equities research analysts expect NuVasive, Inc. (NASDAQ:NUVA) to announce $260.48 million in sales for the current quarter, according to Zacks. Six analysts have made estimates for NuVasive’s earnings. The lowest sales estimate is $259.30 million and the highest is $261.59 million. NuVasive posted sales of $249.86 million during the same quarter last year, which suggests a positive year-over-year growth rate of 4.3%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, April 24th.
On average, analysts expect that NuVasive will report full year sales of $260.48 million for the current fiscal year, with estimates ranging from $1.09 billion to $1.10 billion. For the next financial year, analysts forecast that the business will post sales of $1.15 billion per share, with estimates ranging from $1.15 billion to $1.17 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover NuVasive.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Monday, February 26th. The medical device company reported $0.56 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.56. NuVasive had a net margin of 8.06% and a return on equity of 13.40%. The company had revenue of $271.70 million during the quarter, compared to the consensus estimate of $272.11 million. During the same period in the previous year, the business earned $0.53 earnings per share. The firm’s quarterly revenue was up .2% on a year-over-year basis.
In related news, CEO Gregory T. Lucier bought 6,000 shares of the firm’s stock in a transaction on Tuesday, March 6th. The shares were purchased at an average price of $50.30 per share, with a total value of $301,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB bought a new stake in shares of NuVasive during the fourth quarter worth $293,000. MetLife Investment Advisors LLC bought a new stake in shares of NuVasive during the fourth quarter worth $3,272,000. Westside Investment Management Inc. grew its stake in shares of NuVasive by 76.0% in the fourth quarter. Westside Investment Management Inc. now owns 2,640 shares of the medical device company’s stock worth $147,000 after purchasing an additional 1,140 shares during the last quarter. Macquarie Group Ltd. bought a new stake in shares of NuVasive in the fourth quarter worth $19,094,000. Finally, Meadow Creek Investment Management LLC grew its stake in shares of NuVasive by 22.0% in the fourth quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the medical device company’s stock worth $429,000 after purchasing an additional 1,326 shares during the last quarter.
NuVasive (NUVA) traded down $1.26 during midday trading on Wednesday, hitting $50.88. 751,902 shares of the stock were exchanged, compared to its average volume of 985,119. The company has a current ratio of 3.48, a quick ratio of 1.94 and a debt-to-equity ratio of 0.73. NuVasive has a 52 week low of $44.62 and a 52 week high of $81.68. The firm has a market capitalization of $2,672.52, a P/E ratio of 33.04, a price-to-earnings-growth ratio of 1.33 and a beta of 0.50.
ILLEGAL ACTIVITY WARNING: “NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $260.48 Million” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2018/03/19/nuvasive-inc-nuva-expected-to-announce-quarterly-sales-of-260-48-million.html.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.